Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers ILM, Thompson N, Vanella V, Gerard CL, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan RJ, Long GV, Menzies AM. Owen CN, et al. Among authors: bhave p. Ann Oncol. 2021 Jul;32(7):917-925. doi: 10.1016/j.annonc.2021.03.204. Epub 2021 Mar 30. Ann Oncol. 2021. PMID: 33798657 Free article.
Mortality due to immunotherapy related hepatitis.
Bhave P, Buckle A, Sandhu S, Sood S. Bhave P, et al. J Hepatol. 2018 Oct;69(4):976-978. doi: 10.1016/j.jhep.2018.06.012. Epub 2018 Aug 6. J Hepatol. 2018. PMID: 30093162 No abstract available.
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.
Weppler AM, Pattison A, Bhave P, De Ieso P, Raleigh J, Hatzimihalis A, Gill AJ, Balachander S, Callahan J, Chua M, Au-Yeung G, McArthur GA, Hicks RJ, Tothill RW, Sandhu S. Weppler AM, et al. Among authors: bhave p. J Immunother Cancer. 2020 Oct;8(2):e000700. doi: 10.1136/jitc-2020-000700. J Immunother Cancer. 2020. PMID: 33060145 Free PMC article.
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Bhave P, et al. Br J Cancer. 2021 Feb;124(3):574-580. doi: 10.1038/s41416-020-01121-y. Epub 2020 Oct 22. Br J Cancer. 2021. PMID: 33087895 Free PMC article.
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Patrinely JR Jr, et al. Among authors: bhave p. JAMA Oncol. 2021 May 1;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051. JAMA Oncol. 2021. PMID: 33764387 Free PMC article.
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, Zimmer L, Kapiteijn EW, Allayous C, Johnson DB, Hepner A, Mangana J, Bhave P, Jansen YJL, Trojaniello C, Atkinson V, Storey L, Lorigan P, Ascierto PA, Neyns B, Haydon A, Menzies AM, Long GV, Lebbe C, van der Veldt AAM, Carlino MS, Sandhu S, van Tinteren H, de Vries EGE, Blank CU, Jalving M. Versluis JM, et al. Among authors: bhave p. Eur J Cancer. 2021 Jul;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Epub 2021 May 7. Eur J Cancer. 2021. PMID: 33971447 Free article.
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Hepner A, Atkinson VG, Larkin J, Burrell RA, Carlino MS, Johnson DB, Zimmer L, Tsai KK, Klein O, Lo SN, Haydon A, Bhave P, Lyle M, Pallan L, Pires da Silva I, Gerard C, Michielin O, Long GV, Menzies AM. Hepner A, et al. Among authors: bhave p. Eur J Cancer. 2021 Aug;153:213-222. doi: 10.1016/j.ejca.2021.04.021. Epub 2021 Jun 29. Eur J Cancer. 2021. PMID: 34214936
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML, Dimitriou F, Lau P, Bhave P, McArthur GA, Zimmer L, Kudura K, Gérard CL, Levesque MP, Michielin O, Dummer R, Cheng PF, Mangana J. Hilbers ML, et al. Among authors: bhave p. Eur J Cancer. 2021 Oct;156:149-163. doi: 10.1016/j.ejca.2021.07.028. Epub 2021 Aug 25. Eur J Cancer. 2021. PMID: 34454317 Free article.
153 results